Why KALA BIO, Inc.’s (KALA) Stock Is Down 5.67%
As of Thursday, June 25, KALA BIO, Inc.’s KALA share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Commentary & Analysis
Why KALA BIO, Inc.’s (KALA) Stock Is Up 6.25%
As of Wednesday, June 24, KALA BIO, Inc.’s KALA share price has surged by 6.25%, which has investors questioning if this is right time to sell.Michael Rose
Why KALA BIO, Inc.’s (KALA) Stock Is Down 8.21%
As of Tuesday, June 23, KALA BIO, Inc.’s KALA share price has dipped by 8.21%, which has investors questioning if this is right time to buy.Michael Rose
Why KALA BIO, Inc.’s (KALA) Stock Is Down 11.02%
As of Tuesday, June 23, KALA BIO, Inc.’s KALA share price has dipped by 11.02%, which has investors questioning if this is right time to buy.Omar Beirat
Why KALA BIO, Inc.’s (KALA) Stock Is Down 5.82%
As of Monday, June 22, KALA BIO, Inc.’s KALA share price has dipped by 5.82%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | KALA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $14.1 | $252.6 | 8% |
|
| Shares Out (Mil) | 11.9 | 52.3 | 23% |
|
| Institutional Ownership | 98.8% | 92.1% | 82% |
|
| Float (Mil) | 18.6 | 40.2 | 28% |
|
| Beta | -2.41 | 0.95 | 0% |
|
| Avg Daily Volume (000s) | 100 | 455 | 36% |
|
| Price Change (52-week) |
(99.8%) | 52.9% | 0% |
|
| Growth | KALA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 23.7% | (9.9%) | 78% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 7.5% | (15.6%) | 69% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | KALA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($20) | ($43) | 24% |
|
| EPS (TTM) | ($6.341) | ($1.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($26) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | ($41) | $5 | 21% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $38 | $180 | 14% |
|
| Valuation | KALA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.30 | 2.56 | 33% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KALA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (64.9%) | (49.8%) | 9% |
|
| ROE | (238.7%) | (55.5%) | 4% |
|
| Liabilities to Assets | 12.6% | 30.3% | 8% |
|
| F-Score | 3 | 3 | 19% |
|
KALA BIO, Inc. did not pass any screens on 7/31/2026.
